These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 14967808)

  • 1. Kinetics and specificity of fas ligand induction in toxic epidermal necrolysis.
    Chang HY; Cooper ZA; Swetter SM; Marinkovich MP
    Arch Dermatol; 2004 Feb; 140(2):242-4. PubMed ID: 14967808
    [No Abstract]   [Full Text] [Related]  

  • 2. Toxic epidermal necrolysis treated with low-dose intravenous immunoglobulin: immunohistochemical study of Fas and Fas-ligand expression.
    Ito K; Hara H; Okada T; Shimojima H; Suzuki H
    Clin Exp Dermatol; 2004 Nov; 29(6):679-80. PubMed ID: 15550154
    [No Abstract]   [Full Text] [Related]  

  • 3. [Epidermic necrolysis: advances in pathogenesis].
    Roujeau JC
    Ann Dermatol Venereol; 2000 May; 127(5):546-7. PubMed ID: 10863193
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunohistochemical evaluation of toxic epidermal necrolysis treated with human intravenous immunoglobulin.
    Romanelli P; Schlam E; Green JB; Trent JT; Ricotti C; Elgart GW; Kirsner RS; Kerdel FA
    G Ital Dermatol Venereol; 2008 Aug; 143(4):229-33. PubMed ID: 18833079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A marked increase in serum soluble Fas ligand in drug-induced hypersensitivity syndrome.
    Tohyama M; Shirakata Y; Sayama K; Hashimoto K
    Br J Dermatol; 2008 Sep; 159(4):981-4. PubMed ID: 18637896
    [No Abstract]   [Full Text] [Related]  

  • 6. Diagnostic role of soluble fas ligand secretion by peripheral blood mononuclear cells from patients with previous drug-induced blistering disease: a pilot study.
    Lan CC; Wu CS; Tsai PC; Chen GS
    Acta Derm Venereol; 2006; 86(3):215-8. PubMed ID: 16710577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment.
    Murata J; Abe R; Shimizu H
    J Allergy Clin Immunol; 2008 Nov; 122(5):992-1000. PubMed ID: 18692887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raised plasma soluble Fas and Fas-ligand in alcoholic liver disease.
    Taïeb J; Mathurin P; Poynard T; Gougerot-Pocidalo MA; Chollet-Martin S
    Lancet; 1998 Jun; 351(9120):1930-1. PubMed ID: 9654266
    [No Abstract]   [Full Text] [Related]  

  • 9. The CD40/CD40 ligand system is expressed in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum.
    Caproni M; Torchia D; Schincaglia E; Volpi W; Frezzolini A; Schena D; Marzano A; Quaglino P; De Simone C; Parodi A; Barletta E; Fabbri P
    Br J Dermatol; 2006 Feb; 154(2):319-24. PubMed ID: 16433803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analytical quantification of the inflammatory cell infiltrate and CD95R expression during treatment of drug-induced toxic epidermal necrolysis.
    Paquet P; Jacob E; Damas P; Pirson J; Piérard G
    Arch Dermatol Res; 2005 Dec; 297(6):266-73. PubMed ID: 16249890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental staphylococcal toxic epidermal necrolysis (TEN) in adult humans and mice.
    Elias PM; Fritsch P; Tappeiner G; Mittermayer H; Wolff K
    J Lab Clin Med; 1974 Sep; 84(3):414-24. PubMed ID: 4851979
    [No Abstract]   [Full Text] [Related]  

  • 12. Similar serum levels of soluble forms of fas and fas ligand in cutaneous T cell lymphoma and benign lymphocyte-mediated dermatoses: relevancy for defective apoptosis hypothesis.
    Dereure O; Llanos F; Portales P; Clot J; Guilhou JJ
    J Invest Dermatol; 2002 May; 118(5):895-6. PubMed ID: 11982773
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical importance of circulating and cellular expression levels of Fas and Fas ligand in pediatric patients with lymphoproliferative malignancies.
    Hazar V; Berber Z; Pestereli E; Coskun M; Yesilipek A; Karpuzoglu G; Yegin O
    Pediatr Hematol Oncol; 2005; 22(3):247-56. PubMed ID: 16020109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble Fas and Fas ligand provide new information on metastasis and response to chemotherapy in SCLC patients.
    Shimizu M; Kondo M; Ito Y; Kume H; Suzuki R; Yamaki K
    Cancer Detect Prev; 2005; 29(2):175-80. PubMed ID: 15829378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Borchers AT; Lee JL; Naguwa SM; Cheema GS; Gershwin ME
    Autoimmun Rev; 2008 Sep; 7(8):598-605. PubMed ID: 18603022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of soluble FAS, FAS ligand and tumour necrosis factor-alpha in patients with chronic HCV infection.
    Raghuraman S; Abraham P; Daniel HD; Ramakrishna BS; Sridharan G
    J Clin Virol; 2005 Sep; 34(1):63-70. PubMed ID: 16087126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No increase in soluble Fas and Fas ligand in Kawasaki disease: comment on the article by Nozawa et al.
    Koga M; Hasegawa S; Furukawa S
    Arthritis Rheum; 1998 Mar; 41(3):568-70. PubMed ID: 9506592
    [No Abstract]   [Full Text] [Related]  

  • 18. Serum levels of the Th1 promoter IL-12 and the Th2 chemokine TARC are elevated in erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis and correlate with soluble Fas ligand expression. An immunoenzymatic study from the Italian Group of Immunopathology.
    Quaglino P; Caproni M; Antiga E; Del Bianco E; Osella-Abate S; Savoia P; Frezzolini A; Schena D; Marzano A; Volpi W; De Simone C; Parodi A; Fabbri P; Bernengo MG;
    Dermatology; 2007; 214(4):296-304. PubMed ID: 17460400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxic epidermal necrolysis.
    Seifter EJ; Provost TT; Farmer ER
    Johns Hopkins Med J; 1982 Dec; 151(6):326-31. PubMed ID: 7176292
    [No Abstract]   [Full Text] [Related]  

  • 20. FAS/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer.
    Nadal C; Maurel J; Gallego R; Castells A; Longarón R; Marmol M; Sanz S; Molina R; Martin-Richard M; Gascón P
    Clin Cancer Res; 2005 Jul; 11(13):4770-4. PubMed ID: 16000573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.